SRNE - Mount Sinai licenses antibodies to Sorrento for SARS-CoV-2 treatments

The Icahn School of Medicine at Mount Sinai has agreed to license to Sorrento Therapeutics (SRNE) antibodies that have neutralizing properties against SARS-CoV-2, the virus that caused COVID-19.Mount Sinai and Sorrento are working on the COVISHIELD program, which is intended to discover combinations of monoclonal antibodies (mAbs) that protect against current and emerging variants of SARS-CoV-2.Sorrento has identified potential mAb cocktails currently undergoing studies that could be effective against the U.K, South Africa, and Japan/Brazil SARS-CoV-2 variants.Separately, Sorrento's intravenous STI-2020 (COVI-AMG) is currently in phase 2 studies for mild-to-moderate COVID-19 patients both in and out of the hospital.Sorrento shares are up 9.7% to $9.64 in afternoon trading.

For further details see:

Mount Sinai licenses antibodies to Sorrento for SARS-CoV-2 treatments